SNSE
Sensei Biotherapeutics, Inc.NASDAQHealthcare$31.71+5.03%ClosedMarket Cap: $40.0M
As of 2026-04-09
Valuation
P/E (TTM)
—
PEG
—
P/B
2.15
P/S
-8.25
EV/EBITDA
-1.57
DCF Value
$5.68
FCF Yield
-51.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
459.5%
Net Margin
434.7%
ROE
-83.6%
ROA
-92.1%
ROIC
-110.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | Infinity% | $-5.0M | $-4.7M | $-8.92 | — |
| FY 2025 | $0.00 | NaN% | $-22.3M | $-21.1M | $-16.72 | — |
| Q3 2025 | $-4.9M | 0.0% | $-4.9M | $-4.6M | $-3.62 | — |
| Q2 2025 | $0.00 | -Infinity% | $-5.2M | $-4.9M | $-3.91 | — |
| Q1 2025 | $0.00 | -Infinity% | $-7.3M | $-6.9M | $-0.27 | — |
| Q4 2024 | $0.00 | -Infinity% | $-7.3M | $-7.8M | $-0.31 | — |
| FY 2024 | $0.00 | -Infinity% | $-31.7M | $-30.2M | $-1.20 | — |
| Q3 2024 | $0.00 | -Infinity% | $-7.8M | $-7.3M | $-0.29 | — |
| Q2 2024 | $0.00 | -Infinity% | $-7.8M | $-7.1M | $-0.28 | — |
| Q1 2024 | $0.00 | -Infinity% | $-8.7M | $-8.0M | $-0.32 | — |
| Q4 2023 | $0.00 | -Infinity% | $-8.1M | $-7.4M | $-0.30 | — |
| FY 2023 | $0.00 | -Infinity% | $-37.1M | $-34.1M | $-1.22 | — |